# Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents

> **NCT00712829** · PHASE1 · COMPLETED · sponsor: **Molecular Insight Pharmaceuticals, Inc.** · enrollment: 12 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** 123-I-MIP-1072
- **DRUG:** 123-I-MIP-1095

## Key facts

- **NCT ID:** NCT00712829
- **Lead sponsor:** Molecular Insight Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2011-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00712829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00712829, "Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00712829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*